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Background: Inspired concentrations of desflurane ≥ 1 minimum alveolar anesthetic concentration (MAC) have 
been related to sympathetic stimulation such as hypertension and tachycardia. The current study examined whether 
labetalol, an α1 and β­adrenergic antagonist would blunt these hemodynamic responses. 
Methods: Fifty­four ASA physical status I patients, aged 20-60 years, were enrolled in this study. The patients were 
randomly divided into 2 groups. The breathing circuit was primed with an end­tidal desflurane concentration of 1.2 
MAC in 6 L/min O2. Normal saline 5 ml or labetalol 0.3 mg/kg was injected into groups S and L respectively. After 5 
minutes, anesthesia was induced with intravenous etomidate 0.2 mg/kg and vecuronium 0.1 mg/kg. Each patient 
inhaled desflurane through a tight fitting facemask. Heart rate (HR), systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean arterial pressure (MAP) and end­tidal concentration of desflurane (et­des) were measured at 5 
minutes after saline or labetalol injection (baseline) and every 1 minute for 5 minutes after desflurane inhalation and 
for 2 minutes after intubation.
Results: In the saline injection group (group S), desflurane inhalation increased heart rate and blood pressure, while 
labetalol 0.3 mg/kg attenuated the heart rate and blood pressure increase in group L. After tracheal intubation, heart 
rate and blood pressure were significantly lower in group L than in group S.
Conclusions: These results demonstrate that administration of intravenous labetalol is effective in attenuating 
tracheal intubation and desflurane­induced hemodynamic responses. (Korean J Anesthesiol 2012; 62: 245­250)
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Introduction 
Desflurane is useful for rapid induction and recovery from 
anesthesia because of its lower coefficients of blood solubility 
when compared to other volatile anesthetics. However, a rapid 
increase of desflurane concentration to value ≥ 1 minimum 
alveolar concentration (MAC) can cause hypertension and 
tachycardia by sympathetic activation [1]. It can also intensify 
cardiovascular activity during induction of general anesthesia 
due to hemodynamic changes of endotracheal intubation. 
This could be a serious complication leading to myocardial 
ischemia in a patient suffering from cardiovascular disease 
[2]. Therefore, a variety of methods have been investigated to 
control a sympathetic stimulation by desflurane [1,3,4]. Opioids 
can be only used clinically and esmolol, a β­adrenergic receptor 
blocker, attenuated the heart rate response but no other 
response [1]. By comparison, labetalol, a combined blocker of 
α1, β­receptor, reaches its peak effect at 5 to 15 minutes after 
intravenous injection and rapidly redistributes (5.9 minutes 
redistribution half­life) [5]. Therefore, it is possible that labetalol 
can attenuate tachycardia and hypertension by an inhalation 
of desflurane when inducing anesthesia. However, there have 
been no studies concerning the effect of labetalol on desflurane 
inhalation. The aim of this study was to determine the blunting 
effects of labetalol on desflurane­induced hemodynamic 
responses during induction of general anesthesia. 
Materials and Methods 
After approval by the clinical research committees, 54 
American Society of Anesthesiologists physical status I patients 
between 20-60 years old submitted their written informed 
consent to be included in this study. The patients were 
scheduled for operations for treatment of stomach cancer, large 
intestine cancer, uterine cancer, ovarian cancer, or middle ear 
infection (myringoplasty and tympano  plasty). The patients with 
cardiovascular, respiratory or central nervous system disease, 
a difficulty in maintaining their airway upon induction of 
anesthesia, and subject with a blood pressure ≥ 140/90 mmHg 
after arriving for operation and then resting for 10 minutes were 
excluded from the study. Patients with bradycardia (HR < 45 
beats/min), or severe hypotension on inducing anesthesia 
(decreasing BP > 30% rather than mean arterial pressure just 
before labetalol/saline injection or systolic pressure < 80 
mmHg) were excluded from the study and an endotracheal 
intubation was performed after adequate treatment. The 
patients were randomly divided one of 2 groups (group S and 
group L). Group S (control group) was injected with 5ml of 
normal saline and group L (experimental group) was injected 5 
ml of labetalol (0.3 mg/kg).
We entered patient data (age, height and weight) into the 
anesthesia monitor equipped with a multi gas analyzer (S/5
TM 
Compact anesthesia monitor, GE healthcare, Finland). The 
breathing circuit was earlier primed with 1.2 MAC desflurane 
in O2 6 L/min. The gas collection tube was attached between 
a Y­furcation and a facial mask to check end tidal desflurane 
concentration. We did not performed premedication. Patients 
were monitored HR, pulse­oximetry, capnography, BP and 
end­tidal desflurane concentration. Patients were injected with 
labetalol or saline. Five minutes later, we injected etomidate (0.2 
mg/kg) and vecuronium (0.1 mg/kg) for induction of anesthesia. 
A research assistant attached a facial mask connecting an 
anesthesia circuit filled with desflurane on the face of the 
patient to minimize any leakage and ventilated with a tidal 
volume 10 ml/kg, respiratory rate 10/min after confirming loss 
of consciousness. Intubation was attempted 5 minutes after the 
start of desflurane inhalation. HR, BP and end tidal desflurane 
concentration were recorded at labetalol or saline pre­injection, 
just before desflurane inhalation (5 minutes after labetalol 
or saline injection, baseline), every minute for 5 minutes 
after desflurane inhalation, immediately and 2 minutes after 
intubation. Side effects observed during the study included 
severe hypertension (increasing systolic BP ≥ 180 mmHg) and 
tachy  cardia (HR ≥ 130 beats/min) and were recorded before 
and after endotracheal intubation. Other side effects including 
serious hypotension, arrhythmia, laryngeal, and bronchial 
spasm were recorded prior to the operation. 
Twenty­three patients were required in each group to detect 
a difference of mean arterial pressure between group L and 
group S, with the standard deviation (SD) 8.62 mmHg for 95% 
power and an α value of 0.05. The sample size of 27 patients in 
each group was determined considering a 10% failure rate for 
data collection. Results were analyzed by SPSS (version 18.0, 
SPSS Inc., USA) and the data was expressed as the mean ± 
SD or the number of patients. The comparison of age, height, 
and weight were done using the independent t­test, and the 
gender and occurrence of side­effects was compared by a Chi­
square test. The changes of hemodynamic data and end tidal 
desflurane concentration in each group were analyzed by 
repeated ANOVA. The comparisons of blood pressure, heart rate 
and end tidal desflurane concentration between group S and 
group L were performed as follows. The differences between 
baseline and hourly measurements were calculated in each 
group and then it was determined whether these variations at 
each measurement time showed significant difference between 
the each group by using an independent t­test. A P value < 0.05 
was considered statistically significant.247 www.ekja.org
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Results 
There were no differences between group S and group L in 
the gender, age, weight, and height (Table 1). The hemodynamic 
data just before labetalol or saline injection also were not 
significantly different between the groups (Fig. 1 and 2). Within 
5 minutes after labetalol injection (just before desflurane, 
baseline), HR (group S 70.11 ± 11.91 beats/min, group L 72.74 
± 9.03 beats/min) declined relative to rates before labetalol 
injection (group S 72.96 ± 12.32 beats/min, group L 78.78 ± 
Table 1. Demographic Data
Group S (n = 27) Group L (n = 27)
Age (yr)
Sex (M/F)
Height (cm)
Weight (kg)
  41.26 ± 10.45
6/21
159.07 ± 9.19
 58.38 ± 9.47
  41.89 ± 9.71
5/22
 161.67 ± 7.96
  61.90 ± 9.05
Values are expressed as mean ± SD or number of patients. Group S: 
normal saline, Group L: labetalol 0.3 mg/kg. 
Fig. 2. Changes in systolic (A) and diastolic blood pressure (B) and 
mean arterial pressure (C). Group L: labetalol 0.3 mg/kg, Group S: 
normal saline. Pre L: just before intravenous injection of labetalol 
or normal saline. L5: baseline and 5 min after intravenous 
injection of labetalol or normal saline, just before desflurane 
inhalation. At 1, 2, 3, 4, 5: 1, 2, 3, 4, 5 min after desflurane 
inhalation. PI, PI2: immediately, 2 min after intubation. *P < 0.05 
compared with baseline value (L5) within the group. 
†P < 0.05 
compared with the corresponding values of group S.
Fig. 1. Changes in heart rate. Group L: labetalol 0.3 mg/kg, Group S: 
normal saline. Pre L: just before intravenous injection of labetalol or 
normal saline. L5: baseline and 5 min after intravenous injection of 
labetalol or normal saline, just before desflurane inhalation. At 1, 2, 3, 
4, 5: 1, 2, 3, 4, 5 min after desflurane inhalation. PI, PI2: immediately, 
2 min after intubation. *P < 0.05 compared with baseline value (L5) 
within the group. 
†P < 0.05 compared with the corresponding values 
of group S.248 www.ekja.org
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11.24 beats/min) in both groups (P < 0.05), but BP did not show 
a significant change (Fig. 1 and 2). There were no significant 
differences in the HR and BP between two groups at that time 
(Fig. 1 and 2).
The end tidal desflurane concentrations in the primed 
anesthesia circuit before induction of anesthesia were 1.28 ± 
0.07 MAC in group S and 1.26 ± 0.07 MAC in group L. There 
were no significant differences between the groups. The end 
tidal concentration at 1 minute after desflurane inhalation was 
0.83 ± 0.07 in group S and 0.84 ± 0.07 MAC, and reached 1 MAC 
within 3 minutes in both groups. End tidal concentration was 
calculated as 1.09 ± 0.04 MAC in group S and 1.07 ± 0.07 MAC 
in group L at 2 minutes after endotracheal intubation, and 
there were no noticeable differences between the degrees of 
increasing end tidal concentration with increasing time (Fig. 3).
After desflurane inhalation ranging 1 to 5 minutes, HR had 
significantly increased as compared to baseline, and peaked 
in 2 minutes in group S (P < 0.05) (Fig. 1). In group L, HR 
significantly increased as compared to baseline after desflurane 
inhalation after 1 minute (P < 0.05) (Fig. 1). Group S had higher 
values than group L when comparing the degree of increasing 
heart rate resulting from desflurane inhalation (P < 0.05) (Fig. 1). 
HR increased significantly when compared with baseline in both 
groups after intubation, but the increasing rates of group S were 
greater than those in group L (P < 0.05) (Fig. 1). 
Systolic and diastolic blood pressure increased significantly 
after desflurane inhalation and reached a peak within 2 minutes 
in group S, but then decreased after 2 minutes (P < 0.05) (Fig. 
2). In group L, the BP decreased after desflurane inhalation 
and had significantly low values as compared baseline from 
three to five minutes after desflurane inhalation (P < 0.01) (Fig. 
2). Group S had been greater than group L in the increasing 
degree of systolic and diastolic blood pressure according to 
desflurane inhalation (P < 0.01) (Fig. 2). Systolic and diastolic 
blood pressure immediately after endotracheal intubation 
increased significantly as compared to baseline, but the degrees 
of increase in group S were much higher than in group L (P < 
0.05) (Fig. 2). 
Mean arterial pressure (MAP) increased significantly from 
1 to 4 minutes after desflurane and reached peaks at 2 minutes 
in group S (P < 0.05) (Fig. 2). In group L, MAP was lower than 
baseline from 2 to 5 minutes after desflurane inhalation (P < 
0.05) (Fig. 2). MAP increased immediately after intubation (P < 
0.01) (Fig. 2). The degree of increase in group S was higher than 
in group L according to desflurane inhalation (P < 0.01) (Fig. 2). 
Three subjects had severe hypertension in group S after 
desflurane inhalation through a facial mask, but there were 
no statistical differences between group S and group L (Table 
2). After endotracheal intubation 10 subjects had severe 
hypertension in group S, and there was a noticeable difference 
when comparing the 2 groups (Table 2). However, there was 
no difference in frequency of severe tachycardia (3 subjects 
in group S, none in group L) (Table 2). In addition, there were 
no side effects of hypotension (≤ 80 mmHg of systolic BP or 
decreasing 30% more than baseline in MAP), bradyrhythmia 
(≤ 45 beats/min), arrhythmia, laryngospasm or bronchospasm. 
Discussion 
In this study, patients in the saline injection group showed 
the same pattern as those in previous studies where blood 
pressure and heart rate temporarily increased after desflurane 
inhalation and then gradually decreased [3,6,7]. Although 
it is uncommon that hemodynamic responses produced by 
desflurane are actually harmful to patients, there are studies 
documenting the occurrence of severe tachycardia (HR > 160 
beats/min) or hypertension (systolic BP > 200 mmHg) during 
induction of anesthesia [3,6,7]. We also found a case of severe 
systolic hypertension (> 180 mmHg). In addition, it could be 
that desflurane inhalation temporarily increased the blood 
Fig. 3. Changes in end-tidal concentration of desflurane (MAC). 
There are no significant differences between the 2 groups. Group 
L: labetalol 0.3 mg/kg, Group S: normal saline. L5: 5 min after 
intravenous injection of labetalol or normal saline, just before 
desflurane inhalation. At 1, 2, 3, 4, 5: 1, 2, 3, 4, 5 min after desflurane 
inhalation. PI, PI2: immediately, 2 min after intubation.
Table 2. Incidence of the Side Effects
Group S (n = 27) Group L (n = 27)
Hypertension     Preintubation
                                 Postintubation
Tachycardia        Preintubation
                                 Postintubation
3
10
0
3
0
 0*
0
0
Values are number of patients. Hypertension: ≥ 180 mmHg of systolic 
blood pressure. Tachycardia: ≥ 130 beats/min. Group S: normal 
saline, Group L: labetalol 0.3 mg/kg. *P < 0.05 compared with group S.   249 www.ekja.org
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pressure and heart rate, but no case has been reported where 
desflurane inhalation caused myocardial ischemia in patients 
who had coronary artery disease [2].
Studies have not revealed the mechanism of hemodynamic 
response to desflurane, but it is considered that temporal 
activation of the sympathetic nervous system may be a main 
cause [8]. Diverse methods including medications (fentanyl, 
esmolol and lidocaine), and controlling of the rate of increase 
in inhaled desflurane concentration have been used to reduce 
these hemodynamic responses [1,3,4]. Opioids such as fentanyl 
effectively controlled hypertension and tachycardia caused by 
inhalation of desflurane [1]. In contrast, esmolol and lidocaine, 
and slow increases in desflurane concentration were effective to 
attenuate increase of HR, but not increase of BP [1,3,4]. In this 
study, HR was increased temporally at 1 minute after desflurane 
inhalation in the labetalol group but the range of increase 
was less than in the saline group. In addition, it showed that 
BP after desflurane inhalation lower than baseline. Although 
there were increases of HR and BP immediately after desflurane 
inhalation in a fentanyl (4.5 μg/kg) pre­injection study, Weiskopf 
et al. [1] suggested that fentanyl could effectively control the 
hemodynamic response to desflurane. Therefore, labetalol may 
have been effective in controlling hemodynamic response to 
desflurane. This result presumes that labetalol, a combined 
blocker of α1, β­receptor, attenuated hypertension and tachy­
cardia resulting from an increase of systemic vascular resistance 
and blood catecholamine by desflurane inhalation [8]. 
Endotracheal intubation would cause excessive hypertension 
and tachycardia due to an activation of the sympathetic ner­
vous system. Desflurane­administrated for anesthesia sharply 
increased the level of blood catecholamine and this effect was 
also related to activation of the sympathetic nervous system. 
Normalization of these effects can require more than 10 
minutes [8]. Therefore, it is possible that desflurane intensifies 
cardiovascular reaction to endotracheal intubation during 
induction of anesthesia. In this study, we induced anesthesia 
and started desflurane inhalation 5 minutes after injecting of 
labetalol, and then endotracheal intubation was performed 10 
minutes after labetalol injection. This was because we intended 
to effectively control hemodynamic changes produced by 
desflurane and endotracheal intubation based on the fact that 
the hypotensive effect of labetalol begins 2-5 minustes after 
injection and shows a maximum effect at 5 to 15 minutes [5,9]. 
As a result, even though heart rate and blood pressure had risen 
as compared to baseline values after endotracheal intubation 
in the labetalol group, the level of increase was meaningfully 
lower than in the saline group. In addition, severe hypertension 
and tachycardia occurred in 10 and 3 patients, respectively in 
the saline group, but these effects did not occur in the labetalol 
group. Consequently, labetalol preinjection is thought to be a 
useful method to control hemodynamic responses to not only 
desflurane inhalation but also to endotracheal intubation. 
The increases of HR and BP produced by desflurane were 
temporary, and were reduced as the time of pretreatment 
passed 5 minutes [8]. Therefore, severe hypo  tension and 
brady  cardia could occur when using labetalol, having long 
duration of action [5,9], to block cardiovascular stimulation 
of desflurane. Especially, these risks would have been higher 
from the start of endotracheal intubation to initiating the 
operation because of a lack of stimulation. However, excessive 
hypotension and bradycardia did not occur in this study. This 
could be because the sympathetic nervous system activation 
by desflurane and the use of etomi  date produced lower 
cardiovascular inhibition than other anesthetic inducers for 
anesthesia induction. Labetalol was also rapidly redistributed in 
the body (distribution half­life 5.9 min) and levels in the blood 
were abruptly reduced [5]. It was reported that mean labetalol 
level ≥ 300 mg are required to maintain mean arterial pressure 
at 60 mmHg when middle ear surgery was performed during 80 
minutes under induced hypotension for a normotensive patient 
[10]. In contrast, in this study, labetalol (0.3 mg/kg) was only 
used at a dose of 20 mg for a normal adult (weight 60-70 kg), 
and did not cause an excessive hypotension and bradycardia. 
According to the literature, an injection of labetalol (0.25 mg/
kg) to block cardiovascular reaction during endotracheal 
intubation, produced no hypotension and bradycardia during 
10 minutes after intubation, while maintaining anesthesia 
with propofol [11]. Also, it was reported that BP decreased 
only 17% after a labetalol injection of 1.5 mg/kg [5]. The effect 
of labetalol continues during an operation or after a recovery 
from anesthesia. It is rare for these side effects to occur because 
labetalol has an ability to rapidly redistribute in the body and 
the sympathetic nervous system is activated by pain related to 
an operation. Indeed, in a study of a 20 mg labetalol injection 
in to patients undergoing maxillofacial surgery, hypotension 
and bradycardia did not occur during or after the operation 
[12]. It is thought that the occurrence of severe hypotension 
and bradycardia is rare even though labetalol is used to control 
cardiovascular reaction produced by desflurane. 
Desflurane is not commonly used for pediatric anesthesia 
and patients with respiratory illness such as asthma because of 
a pungent effect on the airway and no bronchodilating effect, 
unlike other inhaled anesthetics [13]. The possibility should 
be considered that simultaneous administration of desflurane 
and a β­adrenergic receptor blocker causes bronchospasm 
because a β­adrenergic receptor blocker such as labetalol can 
attenuate bronchodilation. Common side effects of desflurane 
are cough, breath holding, and laryngospasm [14], but it is 
rare that bronchospasm by desflurane occurs in normal adults 
without a respiratory problem. Moreover, it is reported that 250 www.ekja.org
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labetalol, unlike other β­adrenergic receptors blockers, has 
little impact on the respiratory tract [15,16]. In practice, some 
studies reported that labetalol can be used to treat hypertension 
patients having asthma or chronic bronchitis without 
respiratory side effects [17,18]. Therefore, it is considered 
unlikely that the use of labetalol during desflurane inhalation 
will result in bronchospasm in normal healthy adults. 
Labetalol is initially injected at a dose of 20 mg and injection 
are repeated every 10 minutes according to change of vital signs 
in patients [9]. The labetalol injection dose of 20 mg (in case 
of a normal adult) was only the first time dose investigated in 
this study; however any hemodynamic reaction to desflurane 
was effectively controlled. Therefore, we did not use a higher 
dose of labetalol because the current dose of labetalol was 
sufficient to control a hemodynamic response to desflurane 
and severe hypotension could occur if the dose was increased. 
Studies should be conducted to investigate whether a lower 
dose of labetalol can effectively control cardiovascular reaction 
induced by desflurane because it cannot be excluded that a 
labetalol dose of 0.3 mg/kg causes bronchodilatory inhibition, 
bradycardia, and hypotension. 
In conclusion, BP and HR were rapidly increased in res­
ponse to a ≥ 1 MAC in desflurane concentration, but hemody­
namic response of desflurane inhalation could be effectively 
suppressed by administration of 0.3 mg/kg labetalol. Further­
more, we believe that to some extent, increases of BP and HR by 
endotracheal intubation can be attenuated by labetalol. 
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